Suppr超能文献

肿瘤大小作为局限性胸腺癌的预后因素:一项多中心分析。

Tumor size as a prognostic factor in limited-stage thymic epithelial tumors: A multicenter analysis.

机构信息

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea.

出版信息

J Thorac Cardiovasc Surg. 2021 Jul;162(1):309-317.e9. doi: 10.1016/j.jtcvs.2020.05.048. Epub 2020 May 27.

Abstract

OBJECTIVE

The prognostic significance of tumor size in thymic epithelial tumors (TETs) has not been fully evaluated. We aimed to clarify the prognostic value of tumor size in limited-stage and advanced-stage TETs.

METHODS

Clinical records of patients with completely resected TETs were retrospectively collected from 4 tertiary centers between January 2000 and February 2013. Information on the Masaoka-Koga stage was available for 1215 patients (M-K group), and 433 patients were classified according to the eighth edition of the Tumor-Node-Metastasis staging system (TNM group). Limited-stage and advanced-stage TETs were defined according to whether they were confined within the surrounding fatty tissues without invasion. The optimal cutoff value was selected using a maximally selected log-rank statistic.

RESULTS

The median tumor size was 6.0 ± 2.8 cm in the M-K group and 6.5 ± 3.0 cm in the TNM group. In the multivariable analysis, tumor size had a significant effect on both overall survival (P = .003) and recurrence-free survival (P < .001) for limited-stage tumors (M-K stage I or II or TNM stage I), but not for advanced-stage tumors (M-K stage III or IV or TNM stage II-IV; P = .349 for overall survival and P = .439 for recurrence-free survival). The optimal cutoff value for tumor size was >5.5 cm for both overall survival and recurrence-free survival in limited-stage TETs.

CONCLUSIONS

Tumor size is an independent prognostic factor in patients with completely resected limited-stage TETs and a cutoff value >5.5 cm might help clinicians enact proper treatment strategies and surveillance.

摘要

目的

胸腺瘤(TET)中肿瘤大小的预后意义尚未得到充分评估。本研究旨在明确局限期和进展期 TET 中肿瘤大小的预后价值。

方法

回顾性收集了 4 家三级中心 2000 年 1 月至 2013 年 2 月期间完全切除的 TET 患者的临床记录。1215 例患者(M-K 组)的 Masaoka-Koga 分期资料可用,433 例患者根据第八版肿瘤-淋巴结-转移分期系统(TNM 组)进行分类。局限期和进展期 TET 定义为是否局限于周围脂肪组织而无侵袭。使用最大选择对数秩检验选择最佳截断值。

结果

M-K 组的肿瘤大小中位数为 6.0±2.8cm,TNM 组为 6.5±3.0cm。多变量分析显示,肿瘤大小对局限期肿瘤(M-K Ⅰ或Ⅱ期或 TNM Ⅰ期)的总生存(P=0.003)和无复发生存(P<0.001)均有显著影响,但对进展期肿瘤(M-K Ⅲ或Ⅳ期或 TNM Ⅱ-Ⅳ期)无影响(P=0.349 总生存,P=0.439 无复发生存)。在局限期 TET 中,肿瘤大小>5.5cm 是总生存和无复发生存的最佳截断值。

结论

肿瘤大小是完全切除的局限期 TET 患者的独立预后因素,截断值>5.5cm 可能有助于临床医生制定适当的治疗策略和监测方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验